Portal de investigación
ESTUDIO EPIDEMIOLÓGICO, RETROSPECTIVO, LONGITUDINAL PARA CARACTERIZAR LA HISTORIA NATURAL DE LOS PACIENTES CON CARCINOMA DIFERENCIADO DE TIROIDES AVANZADO EN ESPAÑA Y PORTUGAL.
Datos básicos
- Código:
- EIS-CDT-2017-01
- Protocolo:
- EIS-CDT-2017-01
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2018
- Año de finalización:
- 2018
Objetivos del proyecto
Observaciones: Estado Comité: ACTIVO
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
(18F)FDG-PET-CT in patients with spondylodiscitis: image, clinical and laboratory findings in 10 cases
Bernal, J.; (...); Bello-Arques, P.
Meeting Abstract. 2019
[ 177 Lu]Lu-DOTA-TATE and [ 131 I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center.
Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco
Article. 10.3389/fendo.2022.778322. 2022
177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors
Jimenez-Fonseca, P.; (...); Carmona-Bayonas, A.
Meeting Abstract. 2022
177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
Carmona-Bayonas, A; (...); Jimenez-Fonseca, P
Meeting Abstract. 2020
177-Lu-DOTATATE in 382 patients with somatostatin receptor-positive advanced tumors: Real-world data from the SEPTRALU registry
Casanovas M, Mitjavila; (...); Carmona-Bayonas, A.
Meeting Abstract. 2022
177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations - Data from 552 cases in the SEPTRALU registry
Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2023
177Lu-DOTATATE in advanced neuroendocrine tumours: real word data from SEPTRALU registry
Mitjavila Casanovas, M.; (...); Carmona-Bayona, A.
Meeting Abstract. 2019
A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Capdevila, J; (...); Manzano, JL
Meeting Abstract. 10.1016/j.annonc.2020.08.1373. 2020
A rare case of diffuse and bilateral pulmonary uptake in 18 F-FDG PET/CT scan.
Olivan-Sasot, P; (...); Bello-Arques, P
Editorial Material. 10.1016/j.remn.2020.11.007. 2021
A rare case of diffuse and bilateral pulmonary uptake in 18F-FDG PET/CT scan.
Olivan-Sasot, P; (...); Bello-Arques, P
Article. 10.1016/j.remnie.2020.11.002. 2021
Alternatives of the pelvic sentinel lymph node migration pathway in early ovarian cancer: the simplest the best.
Lago, Victor; (...); Domingo, Santiago
Article. 10.1136/ijgc-2023-004912. 2023
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
Assessment of a well-differentiated pancreatic neuroendocrine tumor with 68 Ga-DOTATOC PET/CT, 68 Ga-DOTATOC PET/MRI and 99m Tc-octreotide SPECT/CT. What does each scan provide?
Prado-Wohlwend, S.; (...); Bello-Arques, P.
Editorial Material. 10.1016/j.remn.2020.05.012. 2021
Assessment of a well-differentiated pancreatic neuroendocrine tumor with 68Ga-DOTATOC PET/CT, 68Ga-DOTATOC PET/MRI and 99mTc-octreotide SPECT/CT. What does each scan provide?
Prado-Wohlwend, S; (...); Bello-Arques, P
Article. 10.1016/j.remnie.2020.08.002. 2021
Autoimmune Diabetes Recurrence After Pancreas Transplantation: Diagnosis, Management, and Literature Review
Argente-Pla, M; (...); Merino-Torres, JF
Review. 10.12659/AOT.920106. 2019
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib.
Jiménez-Fonseca P; (...); Grande E
Article. 10.18632/oncotarget.26380. 2018
Cancer worry at higher-risk sample of hereditary cancer in Spain.
Costa-Requena G, Richart-Aznar P, Segura-Huerta Á
Article. 10.1097/CEJ.0000000000000862. 2024
Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study
Lago, V; (...); Domingo, S
Article. 10.1136/ijgc-2018-000049. 2019
CLINICAL APPLICATION OF THE SENTINEL LYMPH NODE TECHNIQUE IN EARLY OVARIAN CANCER: PHASE II CLINICAL TRIAL
Lago, V.; (...); Domingo, S.
Meeting Abstract. 10.1136/ijgc-2019-ESGO.944. 2019
Clinical experience of whole body and tumour dosimetry of 131-I-mIBG treatment for pediatric patients
Espallardo, I. Torres; (...); Prado-Wohlwend, S.
Meeting Abstract. 2023
Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Gallego, J; (...); Benavent, M
Meeting Abstract. 2018
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; (...); Cross, Nicholas C. P.
Article. 10.1182/bloodadvances.2022008204. 2022
ComBat harmonization in different PET imaging scenarios
Gandia-Ferrero, M.; (...); Marti-Bonmati, L.
Meeting Abstract. 2023
Comparison between whole-body F-18-FDG PET/CT and MRI in patients with SDH gene mutation paragangliomas: a preliminary study
Olivan-Sasot, P; (...); Bello-Arques, P
Meeting Abstract. 2018
Comparison of 3D dosimetry methods in hepatic radioembolisation with Y-90 microspheres
Carrasco Vela, N.; (...); Torres-Espallardo, I.
Meeting Abstract. 2021
Comparison of protocols with respiratory-gated (4D) motion compensation in PET/CT: open-source package for quantification of phantom image quality.
Martinez-Movilla, Andrea; (...); Carles, Montserrat
Article. 10.1186/s40658-022-00509-4. 2022
Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.
Costa-Requena, Gema; (...); Segura-Huerta, Angel
Article. 10.1097/CEJ.0000000000000734. 2022
Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.
Ferrer-Avargues R; (...); Soto JL
Article. 10.1002/cac2.12134. 2021
Correlation Between Clinical Characteristics And Effective Washout Time In Patients Treated With High Radioiodine Activities
Guerrero Calatayud, C.; (...); Bello Arques, P.
Meeting Abstract. 2023
CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.
Sanchis-Pascual, David; (...); Merino-Torres, Juan Francisco
Article. 10.3390/cancers16101799. 2024
Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)
Lopez, C; (...); Rodriguez-Villanueva, J
Meeting Abstract. 10.1016/j.annonc.2020.08.1412. 2020
Do SPECT CT and sentinel node tecnhique increase the diagnosis of metastasic disease in prostate cancer?
Perez Ardavin, J.; (...); Vera-Donoso, C. D.
Meeting Abstract. 2022
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Capdevila, J.; (...); Manzano, J. L.
Article. 10.1038/s41467-023-38611-5. 2023
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A multicenter study
Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2023
Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study.
Mitjavila, Mercedes; (...); Carmona-Bayonas, Alberto
Article. 10.1007/s00259-023-06166-8. 2023
Evaluation of 177Lu-DOTATATE treatment in patients with metastasic or unresectable paragangliomas and pheochromocytomas
Canon Sanchez, J.; (...); Utrera Costero, A.
Meeting Abstract. 2021
Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry
Carmona-Bayonas, A; (...); Garcia-Carbonero, R
Meeting Abstract. 2018
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Jimenez-Fonseca, Paula; (...); Garcia-Carbonero, Rocio
Article. 10.1159/000514808. 2021
FDG-PET/CT Focal Uptake on an Ocular Prosthesis
Repetto, A; (...); Bello, P
Editorial Material. 10.1097/RLU.0000000000002079. 2018
Findings in sentinel lymph node biopsy in 19 patients with ovarian cancer
Utrera, A.; (...); Vera, V.
Meeting Abstract. 2019
Ganglio centinela en cncer de prstata.
Martínez-Sarmiento M; (...); Boronat-Tormo F
Abstract of Published Item. 2019
Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma.
Calsina, Bruna; (...); Robledo, Mercedes
Article. 10.1038/s41467-023-36769-6. 2023
GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome.
Del Olmo García MI, Merino-Torres JF
Article. 10.1016/j.mehy.2019.109504. 2020
GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
del Olmo-Garcia, MI, Merino-Torres, JF
Review. 10.1155/2018/4020492. 2018
Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study
del Olmo-Garcia, MI; (...); Merino-Torres, JF
Article. 10.1177/0300060520926063. 2020
Hepatocarcinoma, our experience with radioembolization treatment
Olivan-Sasot, P; (...); Olivas-Arroyo, C
Meeting Abstract. 2018
I-131-MIBG treatment in patients with metastatic paraganglioma and pheocrhomocytoma
Bernal, J; (...); Bello, P
Meeting Abstract. 2020
Imaging and CSF biomarkers for cognitive impairment
Agudelo, M.; (...); Bello-Arques, P.
Meeting Abstract. 2019
Impact of Diabetes Mellitus in Patients with Pancreatic Neuro-Endocrine Tumors: Causes, Consequences, and Future Perspectives.
Hernandez-Rienda, Lorena, Del Olmo-García MI, Merino-Torres JF
Article. 10.3390/metabo12111103. 2022
Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study
Del Olmo-Garcia, M.; (...); Argente Pla, M.
Meeting Abstract. 2024
Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
Ramirez-Calvo, M; (...); Lopez-Guerrero, JA
Article. 10.1186/s13053-019-0104-x. 2019
Initial Clinical and Treatment Patterns of Advanced Differentiated Thyroid Cancer. ERUDIT Study.
Vallejo Casas, Juan Antonio; (...); Orcajo-Rincon, Lorenzo
Article. 10.1530/ETJ-21-0111. 2022
Just a matter of weight? Final results from NUTRIGETNE study in patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Pla, Argente M.; (...); Del Olmo-Garcia, M.
Meeting Abstract. 2024
Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia
Alonso-Gordoa, T.; (...); de La Cruz, G.
Meeting Abstract. 2022
Less is more: Usefulness of the sentinel node technique in radical prostatectomy
Perez Ardavin, J.; (...); Vera-Donoso, C. D.
Meeting Abstract. 2022
Low activity treatment with I-131 in differentiated thyroid cancer
Olivan-Sasot, P; (...); Bello-Arques, P
Meeting Abstract. 2018
Lu-177-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU
Mitjavila-Casanovas, M.; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2022
Lu-177-DOTATATE Treatment In Unresectable Neuroendocrine Tumors: Our Experience
Agudelo, M; (...); Figueroa-Ardila, G
Meeting Abstract. 2018
Lutetium177 in patients with stage IV neuroendocrine tumours of any origin. Data from 321 patients of the multicenter national registry
Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2021
MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma.
Monteagudo M; (...); Robledo M
Article. 10.1016/j.beem.2024.101931. 2024
Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.
Muñoz de Nova JL; (...); Martin-Perez, Elena
Review. 10.3748/wjg.v28.i13.1304. 2022
Medical imaging clinical trials unit: A professional need.
Penades-Blasco, Ana; (...); Marti-Bonmati, Luis
Article. 10.1016/j.ejrad.2021.110099. 2022
MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Baste Rotllan, N.; (...); Mesia, R.
Meeting Abstract. 10.1016/j.annonc.2023.09.999. 2023
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Nunez-Valdovinos, B; (...); Garcia-Carbonero, R
Article. 10.1634/theoncologist.2017-0364. 2018
Nutritional status of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain - NUTRIGETNE study
Hernandez-Rienda, L.; (...); Del Olmo-Garcia, M.
Meeting Abstract. 2023
Our experience in Sentinel lymph node biopsy after neoadjuvant chemotherapy treatment
Utrera, A; (...); Vera, V
Meeting Abstract. 2020
Pan-Costochondritis Caused by Aspergillus Diagnosed by 18F-FDG PET/CT
Olivan-Sasot, P; (...); Bello-Arques, P
Editorial Material. 10.1097/RLU.0000000000002237. 2018
Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
Mitjavila, M; (...); Jimenez-Fonseca, P
Meeting Abstract. 2019
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE (177Lu) Is Effective and Safe in Patients with Pretreated Metastatic Neuroendocrine Tumors: Data from Spanish SEPTRALU Registry
Bello, P; (...); Mitjavila, M
Meeting Abstract. 2019
Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.
del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.
Article. 10.3390/cancers14030584. 2022
Peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE.
Prado-Wohlwend S; (...); Endocrinology Working Group of the SEMNIM
Article. 10.1016/j.remnie.2021.11.001. 2022
Peptide receptor radionuclide therapy with [Lu-177]Lu-DOTA-TATE
Prado-Wohlwend, S.; (...); SEMNIM
Article. 2022
Pericardial synovial tumor, a rare entity to diagnose by imaging.
Utrera-Costero A; (...); Bernal-Vergara JC
Editorial Material. 10.1016/j.remn.2020.10.005. 2021
Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar, Ariana; (...); Osorio, Santiago
Article. 10.1007/s00277-022-05044-x. 2022
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Benavent M; (...); Gallego J
Article. 10.1186/s12955-021-01688-x. 2021
Pilot performance of a dedicated prostate PET suitable for diagnosis and biopsy guidance
Canizares, G; (...); Gonzalez, AJ
Article. 10.1186/s40658-020-00305-y. 2020
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
Capdevila J; (...); Pubul V
Article. 10.1093/oncolo/oyab041. 2022
Prediction of patient progression-free survival with 177Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection
Mitjavila Casanovas, M.; (...); Carmona-Bayonas, A.
Meeting Abstract. 2024
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; (...); García-Carbonero R
Article. 10.1200/JCO.19.00980. 2019
Preliminary results of activity-time curves analysis in PET/CT F-18-Choline in treated cerebral tumors
Olivan-Sasot, P; (...); Bello-Arques, P
Meeting Abstract. 2018
Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
Fonfria, M; (...); Martinez-Duenas, E
Article. 10.3390/jpm11060548. 2021
Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal
del Olmo-Garcia, MI; (...); Merino-Torres, JF
Review. 10.3390/jcm9072203. 2020
Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) - Data from the national registry SEPTRALU
Bello, P.; (...); Carmona-Bayonas, A.
Meeting Abstract. 2023
Prognostic factors in patients with advanced neuroendocrine tumors treated with 177Lu-DOTATATE
Casanovas, M. Mitjavila; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2018
Proposal of a short acquisition protocol for 18F-DOPA imaging in brain tumors:preliminary results
Orrego, N.; (...); Bello-Arques, P.
Meeting Abstract. 2024
PRRT of 200 patients from the SEPTRALU registry: real-world data
Casanovas, MM; (...); Jimenez-Fonseca, P
Meeting Abstract. 2020
Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
Costa-Requena G; (...); Segura-Huerta Á
Article. 10.1007/s12687-022-00580-5. 2022
Radio theranostics in paragangliomas and pheochromocytomas
Wohlwend, S. Prado, Arques, P. Bello
Article. 10.1016/j.remn.2024.500017. 2024
Radio theranostics in paragangliomas and pheochromocytomas.
Wohlwend SP, Arques PB
Article. 10.1016/j.remnie.2024.500017. 2024
Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases.
Oliván-Sasot P; (...); Olivas-Arroyo C
Article. 10.1016/j.rx.2020.09.012. 2020
Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases.
Olivan-Sasot, P; (...); Olivas-Arroyo, C
Article. 10.1016/j.rxeng.2021.03.001. 2023
Radiological, clinical, scintigraphic and serum markers response of advanced neuroendocrine tumors treated with 177Lu-DOTATATE
Mitjavila Casanovas, M.; (...); Jimenez-Fonseca, P.
Meeting Abstract. 2018
Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study
Mitjavila, CM; (...); Jimenez-Fonseca, P
Meeting Abstract. 2020
Rate of non-invasive follicular thyroid neoplasms with papillary-like nuclear features depends on pathologist's criteria: a multicentre retrospective Southern European study with prolonged follow-up.
Paja, Miguel; (...); Bella, Rosa M.
Article. 10.1007/s12020-021-02610-7. 2021
Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review.
Prado-Wohlwend, Stefan; (...); Merino-Torres JF
Article. 10.3389/fendo.2022.957172. 2022
Retreatment PRRT with 177Lu-DOTATATE in patients with progressive neuroendocrine neoplasm: Spanish clinical experience from national registry
Mitjavila Casanovas, M.; (...); Hernando, J.
Meeting Abstract. 2024
Same-day comparative protocol PET/CT-PET/MRI [68Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine.
Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco
Article. 10.1186/s40644-023-00521-6. 2023
SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas
Bernardo-Castineira C; (...); Chiara MD
Article. 10.1210/jc.2017-01702. 2018
Sentinel lymph node in apparent early ovarian cancer: open technique.
Article. 10.1136/ijgc-2019-000732. 2019
Sentinel lymph node technique in apparent early ovarian cancer: Laparoscopic technique.
Editorial Material. 10.1016/j.jmig.2019.09.790. 2020
SENTINEL LYMPH NODE TECHNIQUE IN EARLY STAGE OVARIAN CANCER (SENTOV): A PHASE II CLINICAL TRIAL
Lago, V.; (...); Domingo, S.
Meeting Abstract. 10.1136/ijgc-2019-ESGO.1284. 2019
Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial
Article. 10.1136/ijgc-2020-001289. 2020
SENTOV (SENTINEL LYMPH NODE TECHNIQUE IN OVARIAN CANCER): VIDEO TECHNIQUE
Lago, V.; (...); Domingo, S.
Meeting Abstract. 10.1136/ijgc-2019-ESGO.1302. 2019
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
Castillón JC; (...); Plazas JG
Article. 10.1007/s12094-023-03205-6. 2023
SEPTRALU registry of 177-Lu-DOTATATE in neuroendocrine tumors: Data from 321 patients in clinical practice
Casanovas, MM; (...); Carmona-Bayonas, A
Meeting Abstract. 2021
Sequential treatment of High-risk Neuroblastoma combining I-131 MIBG high-dose and Topotecan. First experience
Orrego, N.; (...); Bello-Arques, P.
Meeting Abstract. 2023
Simultaneous Pancreas Kidney Transplantation Improves Cardiovascular Autonomic Neuropathy with Improved Valsalva Ratio as the Most Precocious Test
Argente-Pla M; (...); Merino-Torres JF
Article. 10.1155/2020/7574628. 2020
Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.
Del Olmo-Garcia MI; (...); Merino-Torres JF
Article. 10.3390/biomedicines9121810. 2021
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.
Tena, I; (...); Pacak, K
Article. 10.1177/1179554918763367. 2018
Survey for neuroendocrine tumors'standard of care - A multidisciplinary pilot study in Spanish specialists
Sampedro-Nunez, M; (...); Capdevila, J
Meeting Abstract. 2021
The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET)
Molina Cerrillomd, Javier; (...); Capdevila, Jaume
Meeting Abstract. 2023
The Role of Imaging Studies in Favor of Possible Cerebellar Multiple System Atrophy: A Case Study.
Utrera-Costero, Ana; (...); Bello-Arques, Pilar
Article. 10.1097/RLU.0000000000003767. 2021
The sentinel node with technetium-99m for prostate cancer. A safe and, mature new gold standard?
Perez-Ardavin J; (...); Vera-Donoso CD
Article. 10.23736/S1824-4785.22.03416-1. 2022
The value of F-18-FDG PET/CT in two cases of Primary Pericardial Mesothelioma
Utrera-Costero, Ana; (...); Bello-Arques, Pilar
Article. 10.1007/s12350-021-02690-y. 2021
Ultrastaging protocol in sentinel lymph node for apparent early stage ovarian cancer.
Article. 10.1016/j.ygyno.2021.03.001. 2021
Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring
Arenillas, Lallana C.; (...); Toledo, R. A.
Meeting Abstract. 2024
Update on iodine-refractory differentiated thyroid carcinoma
Casas, E. Abou Jokh; (...); Casas, J. A. Vallejo
Article. 10.1016/j.remn.2023.06.005. 2023
Update on iodine-refractory differentiated thyroid carcinoma.
Jokh Casas, E A; (...); Vallejo Casas, J A
Article. 10.1016/j.remnie.2023.07.003. 2023
Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study
Custodio, A; (...); Villabona, C
Article. 10.1007/s12094-021-02608-7. 2021
Use Of Iodine-131 (RAI) For The Initial Diagnosis And Treatment Of Differentiated Thyroid Cancer (DTC) In Spain And Portugal (ERUDIT Study)
Casas, JV; (...); Orcajo, L
Meeting Abstract. 2020
Usefulness Of Post Treatment SPECT/CT In Whole Body Scan For The TNM Re-Staging In Patients With Well Differentiated Thyroid Cancer (WDTC)
Yepes Agudelo, A.; (...); Martinez Sanchis, B.
Meeting Abstract. 2019
Y-90 PET/MR imaging optimization with a Bayesian penalized likelihood reconstruction algorithm.
Calatayud-Jordan, Jose; (...); Torres-Espallardo, Irene
Article. 10.1007/s13246-024-01452-7. 2024